title: Treatment of locally recurrent Epstein-Barr virus-associated nasopharyngeal carcinoma using the anti-viral agent cidofovir.
abstract: Nasopharyngeal carcinoma (NPC) is an Epstein-Barr virus (EBV) associated malignant tumor. Recently, cidofovir, an anti-viral drug which is an acyclic nucleoside analogue, has been reported to have an anti-tumor potential. Two patients with NPC, who had previously received multi-round therapy, were treated with cidofovir. Cidofovir was topically injected in and around the tumor once every 3 weeks (originally 75 mg/ml sulution, diluted to 15 mg/ml just before injection, 37.5 mg of cidofovir at a time). Tumor growth was suppressed for several months around the injection site in each patient. EBV-encoded RNAs in situ hybridization revealed the reduction of the tumor cell population; however, the EBER expression was still maintained in the NPC tumor cells. Although the anti-tumor mechanism remains unclear, these results suggest that cidofovir is actually an effective and safe agent for the treatment of NPC.
authors: Division of Otolaryngology-Head and Neck Surgery, Graduate School of Medicine, Kanazawa University, Kanazawa, Japan. tomoy@med.kanazawa-u.ac.jp
authors: Tomokazu
authors: T
authors: Yoshizaki
authors: Naohiro
authors: N
authors: Wakisaka
authors: Satoru
authors: S
authors: Kondo
authors: Shigeyuki
authors: S
authors: Murono
authors: Yoshinori
authors: Y
authors: Shimizu
authors: Masashi
authors: M
authors: Nakashima
authors: Akira
authors: A
authors: Tsuji
authors: Mitsuru
authors: M
authors: Furukawa
mesh_terms: D000328:Adult; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D000998:Antiviral Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D000077404:Cidofovir; D003596:Cytosine / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000627:therapeutic use; D020031:Epstein-Barr Virus Infections / Q000150:complications* / Q000188:drug therapy*; D006801:Humans; D008279:Magnetic Resonance Imaging; D008297:Male; D009303:Nasopharyngeal Neoplasms / Q000188:drug therapy* / Q000821:virology*; D063065:Organophosphonates / Q000008:administration & dosage / Q000627:therapeutic use*; D010614:Pharynx / Q000000981:diagnostic imaging / Q000473:pathology / Q000821:virology; D016601:RNA-Binding Proteins / Q000096:biosynthesis; D011859:Radiography; D012269:Ribosomal Proteins / Q000096:biosynthesis
chemical_list: D000970:Antineoplastic Agents; D000998:Antiviral Agents; D063065:Organophosphonates; D016601:RNA-Binding Proteins; D012269:Ribosomal Proteins; C067169:RPL22 protein, human; D003596:Cytosine; D000077404:Cidofovir